CS MEDICA has extended the cooperation with their partner Nutrin, manufacturer and R&D partner, on distributing Nutrin’s developed Lozenges protecting against COVID-19 infection
CS MEDICA (“CS Medica” or the “Company”) announces today that the Company has extended its cooperation with its partner Nutrin, manufacture and R&D partner. Nutrin has developed a lozenge that protects against COVID-19 infection. This lozenge in combination with CS MEDICA’s Protective Nasal Gel forms a shield that protects against COVID-19 virus infection.Lone Henriksen, CEO of CS MEDICA, pronounces:
"I am very pleased to announce that CS MEDICA has expanded their product portfolio now also covering protection against COVID-19 virus infection. This opens a new market for the Company